How it works, simply
It restricts iron availability for making red blood cells.
What the evidence tells us
This disease-specific use is not a treatment for ordinary high iron or a general blood-health intervention.
Approved use: United States: Mimrylo for erythrocytosis in adults with polycythemia vera.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
This brief guide does not summarize every contraindication or interaction. Use the current label for the exact product; the label directory is linked below.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Mimics hepcidin to limit iron availability for red-blood-cell production.
Sponsor or developer: Takeda / Protagonist Therapeutics
Studied or labeled topics: Polycythemia vera
2026-08-28: FDA approval of a hepcidin-mimicking treatment for polycythemia vera.
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- FDA: Mimrylo approval announcement ↗ · Regulator · 2026-08-28
- FDA: Mimrylo prescribing information ↗ · Regulator · 2026-08-28
Readability updated October 10, 2026. Evidence review: September 23, 2026 (listed facts only). A wording update is not a new clinical review.